Clinical translation of 177Lu[Lu]-trastuzumab from the laboratory to the clinic for radioimmunotherapy of breast cancer over-expressing HER2 receptors.

The present study indicates that antibody to BFCA ratio plays a crucial role in determining the immunoreactivity and pharmacokinetic behavior of the radiolabeled antibodies and must be prudently chosen for their successful therapeutic application.

The present study demonstrates that the pharmacokinetic behavior of Ga-labeled porphyrin derivatives, prepared using either NOTA or DOTA derivatives as BFCAs, remains almost identical and hence both NOTA and DOTA derivatives could be considered equivalent for developingGa-based PET agents for imaging of tumorous lesions.

No abstract